Diagnostic Accuracy of CAD4TB and C-reactive Protein Assay as Triage Tests for Pulmonary Tuberculosis
NCT04666311 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1400
Last updated 2025-09-22
Summary
In the TB TRIAGE+ ACCURACY study, the accuracy of the following products will be determined:
* CAD4TB (Delft Imaging System, NL), a digital chest x-ray analysis software
* Afinion CRP assay (Alere Afinion, USA), which detects a cytokine induced acute phase protein
CAD4TB and the C-reactive protein assay are two tests with great potential of becoming a triage test for the diagnosis of tuberculosis (TB). These potential triage tests for TB are intended to serve as rule-out tests with a high sensitivity and negative predictive value.
Before impact and cost-effectiveness of new TB triage tests for intensified active case finding can be determined, the diagnostic test accuracy needs to be assessed in comparison to confirmatory reference tests. This accuracy study will define cut-off values for CAD4TB as well as for the Afinion CRP assay to be used in a future cluster-randomised trial on impact and cost-effectiveness of TB triage strategies for intensified active case finding in Lesotho and KwaZulu-Natal, South Africa.
A sub-study (detailed in a separate study protocol), hereafter called AHD-FEASIBILITY, explores the feasibility of implementing a series of point-of-care tests, including the new VISITECT CD4 Advanced Disease Test (Omega Diagnostics, UK) as part of the WHO-recommended advanced HIV Disease care package in the context of community-based HIV/TB campaigns.
Due to the coinciding pandemics and the overlapping symptoms of TB and COVID-19, it is critical to test for SARS-Cov-2 infections in the study population. In addition, this study will contribute to the evaluation of a novel SARS-Cov-2 antigen rapid diagnostic test (from the diagnostic pipeline of FIND) and CAD4COVID, a digital chest x-ray analysis software (Delft Imaging System, NL) in combination with differential white blood cell count.
Conditions
Interventions
- DIAGNOSTIC_TEST
-
Accuracy of CAD4TB and Afinion CRP assay for pulmonary TB
CAD4TB version 6 and 7: Software tool for detecting lung abnormalities in computer tomogram images (pulmonary abnormalities) and frontal chest radiograph images (tuberculosis abnormalities) ; availability is guaranteed by Delft Imaging System; EC 0344 Certificate (vs.6); CE mark pending (vs.7). Will be performed by a registered and qualified radiographer in accordance with national regulations. Afinion AS100 Analyzer and Afinion CRP: In vitro diagnostic to determine the amount of CRP in human whole blood, serum or plasma; CE-mark ; Will be performed by qualified, GCP-trained study personnel.
- DIAGNOSTIC_TEST
-
CAD4COVID+WBC and COVID-19 RDT for SARS-CoV-2 infection
CAD4COVID: Non-commercial product. Software tool for detecting pneumonia-related features to be expected in COVID-19 patients; availability is guaranteed by Delft Imaging System; CE certified. Will be performed by a registered and qualified radiographer/health professional in accordance with national regulations. Analysis in combination with differential white blood cell count. SD Biosensor, STANDARDTM Q COVID-19 Ag Test (rapid chromatographic immunoassay for the qualitative detection of specific antigens to SARS-CoV-2)
Sponsors & Collaborators
-
SolidarMed
collaborator OTHER -
Human Sciences Research Council
collaborator OTHER_GOV -
Institute of Tropical Medicine, Belgium
collaborator OTHER -
Radboud University Medical Center
collaborator OTHER -
Charite University, Berlin, Germany
collaborator OTHER -
University Hospital, Basel, Switzerland
collaborator OTHER -
Foundation for Innovative New Diagnostics, Switzerland
collaborator OTHER -
European and Developing Countries Clinical Trials Partnership (EDCTP)
collaborator OTHER_GOV -
Ministry of Health, Lesotho
collaborator OTHER_GOV -
Klaus Reither
lead OTHER
Principal Investigators
-
Klaus Reither, MD, PhD · Swiss Tropical & Public Health Institute
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2021-02-15
- Primary Completion
- 2022-04-05
- Completion
- 2022-08-11
Countries
- Lesotho
- South Africa
Study Locations
More Related Trials
-
Acceptability and Feasibility of Home-based TB Testing
NCT04973371 ·Status: COMPLETED ·Phase: NA
-
Point-of-care Triage Test for Active Tuberculosis
NCT04232618 ·Status: UNKNOWN
-
TB-CAPT MTB/XDR Study
NCT04567368 ·Status: ACTIVE_NOT_RECRUITING
-
Evaluation of Host Biomarker-based Point-of-care Tests for Targeted Screening for Active TB
NCT03350048 ·Status: COMPLETED
-
Gene Xpert Diagnosis of TB Using Tracheal Aspirates From Intensive Care Unit (ICU) Patients
NCT01530568 ·Status: COMPLETED ·Phase: NA
-
Start Taking Action For TB Diagnosis
NCT05845112 ·Status: COMPLETED
-
Development of a Rapid and Accurate Diagnostic Assay for Tuberculosis
NCT03423550 ·Status: UNKNOWN
-
Xpert Active Case-finding Trial 2: Community-based Active Case-finding for Tuberculosis in South Africa
NCT03168945 ·Status: COMPLETED ·Phase: NA
-
The Utility of Intensified Case Finding Combined With a Package of Novel TB Diagnostics Using a Mobile Clinic in Africa
NCT01990274 ·Status: COMPLETED ·Phase: NA
-
Trial of Point-of-treatment Xpert MTB/RIF Assay
NCT01554384 ·Status: COMPLETED ·Phase: NA
-
Clinical Evaluation of the Truenat Point-of-care Tuberculosis Diagnostic Test
NCT03712709 ·Status: COMPLETED
-
Global Consortium for Drug-resistant Tuberculosis Diagnostics
NCT02170441 ·Status: COMPLETED
-
Assessing the Ability of the T-SPOT®.TB Test
NCT03929705 ·Status: COMPLETED
-
Test to Treat TB: Impact of Sputum Sequencing-guided Individualised Therapy on Outcomes in Drug-resistant Tuberculosis
NCT05007795 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Host Blood RNA Signatures for Diagnosis of TB
NCT05542511 ·Status: ACTIVE_NOT_RECRUITING
-
First-in-Human Trial of the Novel Tuberculosis Vaccine Candidate, H107e/CAF®10b
NCT06050356 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Xpert Active Case-finding Trial 3 (XACT-3)
NCT04303104 ·Status: COMPLETED ·Phase: NA
-
Comparison of Diagnostic Performance of C-Tb to QuantiFERON®-TB, in Combination With a Safety Assessment of C-Tb vs Tuberculin PPD RT23 SSI
NCT01631266 ·Status: COMPLETED ·Phase: PHASE3
-
Clinical Evaluation of an IGRA Test for the Diagnosis of Active and Latent Tuberculosis
NCT06485895 ·Status: RECRUITING ·Phase: NA
-
Evaluation of CAD-based Triage for CXR Interpretation During TB Screening
NCT06401434 ·Status: COMPLETED ·Phase: NA
-
DIAgnostics for Multidrug Resistant Tuberculosis in Africa
NCT03303963 ·Status: COMPLETED
-
TB Host Directed Therapy
NCT02968927 ·Status: UNKNOWN ·Phase: PHASE2
-
Safety, Tolerability, Extended Early Bactericidal Activity and PK of Higher Doses Rifampicin in Adults With Pulmonary TB
NCT01392911 ·Status: COMPLETED ·Phase: PHASE2
-
TB-CAPT CORE Truenat Trial
NCT04568954 ·Status: COMPLETED ·Phase: NA
-
Sensitivity and Specificity of Xpert MTB/RIF Ultra
NCT06058065 ·Status: NOT_YET_RECRUITING